Marc L. Reitman

Marc L. Reitman

Auto-generated profile, based on publicly available information

Marc L. Reitman

Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TYT. Yamauchi
T. Yamauchi
JKJ. Kamon
J. Kamon
HWH. Waki
H. Waki
YTY. Terauchi
Y. Terauchi
NKN. Kubota
N. Kubota
TKT. Kadowaki
T. Kadowaki

16 March 2008 in Nature
Verified
Journal Article
Closed access
PDF file
VEValur Emilsson
Valur Emilsson
GTGudmar Thorleifsson
Gudmar Thorleifsson
BZBin Zhang
Bin Zhang
ALAmy S. Leonardson
Amy S. Leonardson
FZFlorian Zink
Florian Zink
KSKari Stefansson
Kari Stefansson

21 February 2002 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
EOElif Arioglu Oral
Elif Arioglu Oral
VSVinaya Simha
Vinaya Simha
ERElaine Ruiz
Elaine Ruiz
AAAlexa Andewelt
Alexa Andewelt
APAhalya Premkumar
Ahalya Premkumar
AGAbhimanyu Garg
Abhimanyu Garg
The adipocyte hormone leptin is important in regulating energy homeostasis. Since severe lipodystrophy is associated with leptin deficiency, insulin resistance, hypertriglyceridemia, and hepatic steatosis, we assessed whether leptin replacement would ameliorate this condition.

19 June 2005 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ESEric E Schadt
Eric E Schadt
JLJohn Lamb
John Lamb
XYXia Yang
Xia Yang
JZJun Zhu
Jun Zhu
SESteve Edwards
Steve Edwards
ALAldons J Lusis
Aldons J Lusis

28 December 2011 in Nature Methods
Verified
Journal Article
Open access
PDF file
MTMatthias H Tschöp
Matthias H Tschöp
JSJohn R Speakman
John R Speakman
JAJonathan R S Arch
Jonathan R S Arch
JAJohan Auwerx
Johan Auwerx
JBJens C Brüning
Jens C Brüning
EREric Ravussin
Eric Ravussin
Authors present workflows for the analysis of metabolism phenotypes in mice and recommend analysis of covariance to asses body composition effects. We present a consolidated view of the complexity and challenges of designing studies for measurement of energy metabolism in mouse models, including a practical guide to the assessment of energy expenditure, energy intake and body composition and statistical analysis thereof. We hope this guide will facilitate comparisons across studies and minimize spurious interpretations of data. We recommend that division of energy expenditure data by either body weight or lean body weight and that presentation of group effects as histograms should be replaced by plotting individual data and analyzing both group and body-composition effects using analysis of covariance (ANCOVA).

1 September 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
OGOksana Gavrilova
Oksana Gavrilova
MHMartin Haluzík
Martin Haluzík
KMKimihiko Matsusue
Kimihiko Matsusue
JCJaime J. Cutson
Jaime J. Cutson
LJLisa Johnson
Lisa Johnson
MRMarc L. Reitman
Marc L. Reitman
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that mediates the antidiabetic effects of thiazolidinediones. PPARγ is present in adipose tissue and becomes elevated in fatty livers, but the roles of specific tissues in thiazolidinedione actions are unclear. We studied the function of liver PPARγ in both lipoatrophic A-ZIP/F-1 (AZIP) and wild type mice. In AZIP mice, ablation of liver PPARγ reduced the hepatic steatosis but worsened the hyperlipidemia, triglyceride clearance, and muscle insulin resistance. Inactivation of AZIP liver PPARγ also abolished the hypoglycemic and hypolipidemic effects of rosiglitazone, demonstrating that, in the absence of adipose tissue, the liver is a primary and major site of thiazolidinedione action. In contrast, rosiglitazone remained effective in non-lipoatrophic mice lacking liver PPARγ, suggesting that adipose tissue is the major site of thiazolidinedione action in typical mice with adipose tissue. Interestingly, mice without liver PPARγ, but with adipose tissue, developed relative fat intolerance, increased adiposity, hyperlipidemia, and insulin resistance. Thus, liver PPARγ regulates triglyceride homeostasis, contributing to hepatic steatosis, but protecting other tissues from triglyceride accumulation and insulin resistance.